About the Journal

Download [This article belongs to Volume - 140, Issue - 01]

Abstract : The FDA has approved D-tocopheryl polyethylene glycol succinate (Vitamin E TPGS) as a safe pharmacological adjuvant, and many drug delivery procedure rely on TPGS have been designed.TPGS properties as a P-gp inhibitor, solubilizer/absorption and permeation enhancer in drug delivery and TPGS-related formulations such as nanocrystals, nanosuspensions, tablets/solid dispersions, vaccine system adjuvant, nutritional supplement, film plasticizer, anticancer reagent, and so on, are discussed in this review. Consequenly, TPGS can inhibit P-glycoprotein dependent on ATP and act as a robust excipient that promotes the efficiency of delivery and the therapeutic effect of drugs. Inhibition of P-gp occurs through mitochondria-dependent inhibition of the P-gp pump. Many of the latest studies address the use of TPGS for many permeable drugs as well as less soluble medication in the manufacture of nanodrugs or other formulations. Nevertheless, it has been confirmed that TPGS shows a robust improvement in chylomicron secretion at low concentrations and improves intestinal lymphatic transport, which would also boost the potential of drug absorption. It also indicates that there are still many problems facing clinical translation of TPGS-based nanomedicines, requiring a more deep evaluation of TPGS properties and a future-based delivery method.

Copyright © 2020 All rights reserved | Bulletin of National Institute of Health Sciences